
A bacteria that we inherit from our mother is a new food
5 December, 2022Scholarship for the development of research projects
9 December, 2022El investigador ARAID Alberto Jiménez Schuhmacher, head of the Molecular Oncology Group at the Aragón Health Research Institute (IIS Aragón), joined the Royal Academy of Medicine of Zaragoza as corresponding academic. Accompanied by academic and political authorities, in his speech 'Development and characterization of nanoantibodies for the diagnosis and treatment of tumors' he embarked on a journey into the history of precision medicine and antibodies to delve into the lines of research he develops in the IIS Aragón, which include the development of nanoantibodies to perform non-invasive imaging probes, a procedure called virtual biopsy.
During the event, Schuhmacher explained numerous applications of this technology that they are using, such as its modification to be used as fluorescence-guided surgery tools, as a therapy by functionalizing nanoparticles, as the basis of novel advanced therapies, such as CAR-T or as inhibitors of cellular processes. . Currently, his group works on very aggressive tumors such as glioblastoma, diffuse trunk glioma, pancreatic cancer, osteosarcoma or metastatic breast cancer.

The researcher also dedicated some emotional words to his teachers, laboratory colleagues and his family, and ended with some reflections on the figure of Santiago Ramón y Cajal and neurosciences as the next great challenge, warning of the risks they entail.
El laudation It was led by senior academic Caridad Sánchez Acedo, who highlighted not only Schuhmacher's scientific qualities, but also his human values and his role as a communicator of science to society, as well as his involvement with patient associations.